JP2020518591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518591A5 JP2020518591A5 JP2019559744A JP2019559744A JP2020518591A5 JP 2020518591 A5 JP2020518591 A5 JP 2020518591A5 JP 2019559744 A JP2019559744 A JP 2019559744A JP 2019559744 A JP2019559744 A JP 2019559744A JP 2020518591 A5 JP2020518591 A5 JP 2020518591A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- less
- administration
- cell therapy
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 349
- 150000001875 compounds Chemical class 0.000 claims description 281
- 238000002659 cell therapy Methods 0.000 claims description 230
- 230000002519 immonomodulatory effect Effects 0.000 claims description 212
- 210000004027 cell Anatomy 0.000 claims description 188
- 210000004369 blood Anatomy 0.000 claims description 91
- 239000008280 blood Substances 0.000 claims description 91
- 239000000427 antigen Substances 0.000 claims description 85
- 108091007433 antigens Proteins 0.000 claims description 85
- 102000036639 antigens Human genes 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 78
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 78
- 239000003814 drug Substances 0.000 claims description 63
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 62
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 61
- 206010028980 Neoplasm Diseases 0.000 claims description 61
- 102000005962 receptors Human genes 0.000 claims description 61
- 108020003175 receptors Proteins 0.000 claims description 61
- 102100032783 Protein cereblon Human genes 0.000 claims description 60
- 201000010099 disease Diseases 0.000 claims description 56
- 239000003112 inhibitor Substances 0.000 claims description 43
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims description 40
- 241000571697 Icarus Species 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 31
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 24
- 229960003433 thalidomide Drugs 0.000 claims description 24
- 230000015556 catabolic process Effects 0.000 claims description 22
- 238000006731 degradation reaction Methods 0.000 claims description 22
- 230000000977 initiatory effect Effects 0.000 claims description 20
- 230000034512 ubiquitination Effects 0.000 claims description 18
- 238000010798 ubiquitination Methods 0.000 claims description 18
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 230000001605 fetal effect Effects 0.000 claims description 16
- -1 4-amino-1-oxo-1,3-dihydro-2H-isoindole-2-yl Chemical group 0.000 claims description 15
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 15
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 14
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 102000006306 Antigen Receptors Human genes 0.000 claims description 12
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims description 12
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical class CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims description 11
- 108010083359 Antigen Receptors Proteins 0.000 claims description 11
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 10
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 10
- 239000013078 crystal Substances 0.000 claims description 10
- 201000003444 follicular lymphoma Diseases 0.000 claims description 10
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 206010061818 Disease progression Diseases 0.000 claims description 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 9
- 230000005750 disease progression Effects 0.000 claims description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 8
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 8
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 8
- 101150029707 ERBB2 gene Proteins 0.000 claims description 8
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 8
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 8
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 8
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 8
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 8
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 8
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 8
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 8
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 8
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 8
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims description 8
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims description 8
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 8
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 8
- 208000008383 Wilms tumor Diseases 0.000 claims description 8
- 208000026448 Wilms tumor 1 Diseases 0.000 claims description 8
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 8
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 8
- 239000012636 effector Substances 0.000 claims description 8
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- 102000036215 folic acid binding proteins Human genes 0.000 claims description 8
- 108091011001 folic acid binding proteins Proteins 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 8
- 210000003289 regulatory T cell Anatomy 0.000 claims description 8
- 101150047061 tag-72 gene Proteins 0.000 claims description 8
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 201000011184 adult acute lymphocytic leukemia Diseases 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 102100032912 CD44 antigen Human genes 0.000 claims description 4
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 4
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 101150032879 Fcrl5 gene Proteins 0.000 claims description 4
- 108091006027 G proteins Proteins 0.000 claims description 4
- 102000030782 GTP binding Human genes 0.000 claims description 4
- 108091000058 GTP-Binding Proteins 0.000 claims description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 4
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 4
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 4
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 4
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 4
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 4
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 4
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 4
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 4
- 102100023123 Mucin-16 Human genes 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims description 4
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 4
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 claims description 4
- 102000036673 PRAME Human genes 0.000 claims description 4
- 108060006580 PRAME Proteins 0.000 claims description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 4
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 4
- 101800001271 Surface protein Proteins 0.000 claims description 4
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 108091008605 VEGF receptors Proteins 0.000 claims description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 4
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 230000016396 cytokine production Effects 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 4
- 238000006297 dehydration reaction Methods 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- 230000009977 dual effect Effects 0.000 claims description 4
- 108010038795 estrogen receptors Proteins 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 102000006495 integrins Human genes 0.000 claims description 4
- 108010044426 integrins Proteins 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 102000003998 progesterone receptors Human genes 0.000 claims description 4
- 108090000468 progesterone receptors Proteins 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 230000001461 cytolytic effect Effects 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 27
- 230000001225 therapeutic effect Effects 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 241000673185 Aeolus Species 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- IXZOHGPZAQLIBH-UHFFFAOYSA-N 3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(C2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-UHFFFAOYSA-N 0.000 claims 1
- 102000016736 Cyclin Human genes 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 108010060273 Cyclin A2 Proteins 0.000 claims 1
- 102100025191 Cyclin-A2 Human genes 0.000 claims 1
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- 229960000688 pomalidomide Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 117
- 239000008194 pharmaceutical composition Substances 0.000 description 63
- 230000011664 signaling Effects 0.000 description 35
- 230000004068 intracellular signaling Effects 0.000 description 34
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 30
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 description 30
- 230000002354 daily effect Effects 0.000 description 15
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 12
- 108091008874 T cell receptors Proteins 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 238000002617 apheresis Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000031146 intracellular signal transduction Effects 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 3
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 102000046935 human TNFRSF17 Human genes 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 description 1
- 108010013958 Ikaros Transcription Factor Proteins 0.000 description 1
- 102000017182 Ikaros Transcription Factor Human genes 0.000 description 1
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023098900A JP2023116720A (ja) | 2017-05-01 | 2023-06-16 | 細胞療法と免疫調節化合物の併用 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492947P | 2017-05-01 | 2017-05-01 | |
| US62/492,947 | 2017-05-01 | ||
| US201762538670P | 2017-07-29 | 2017-07-29 | |
| US62/538,670 | 2017-07-29 | ||
| US201762549390P | 2017-08-23 | 2017-08-23 | |
| US62/549,390 | 2017-08-23 | ||
| US201762580433P | 2017-11-01 | 2017-11-01 | |
| US62/580,433 | 2017-11-01 | ||
| US201762596753P | 2017-12-08 | 2017-12-08 | |
| US62/596,753 | 2017-12-08 | ||
| PCT/US2018/030545 WO2018204427A1 (en) | 2017-05-01 | 2018-05-01 | Combination of a cell therapy and an immunomodulatory compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098900A Division JP2023116720A (ja) | 2017-05-01 | 2023-06-16 | 細胞療法と免疫調節化合物の併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518591A JP2020518591A (ja) | 2020-06-25 |
| JP2020518591A5 true JP2020518591A5 (enExample) | 2021-06-17 |
| JP7299841B2 JP7299841B2 (ja) | 2023-06-28 |
Family
ID=62563245
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559744A Active JP7299841B2 (ja) | 2017-05-01 | 2018-05-01 | 細胞療法と免疫調節化合物の併用 |
| JP2023098900A Pending JP2023116720A (ja) | 2017-05-01 | 2023-06-16 | 細胞療法と免疫調節化合物の併用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098900A Pending JP2023116720A (ja) | 2017-05-01 | 2023-06-16 | 細胞療法と免疫調節化合物の併用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20200078404A1 (enExample) |
| EP (2) | EP4327878A3 (enExample) |
| JP (2) | JP7299841B2 (enExample) |
| KR (2) | KR20240139092A (enExample) |
| CN (2) | CN118948892A (enExample) |
| AU (2) | AU2018263887B2 (enExample) |
| BR (1) | BR112019022893A2 (enExample) |
| CA (1) | CA3061945A1 (enExample) |
| DK (1) | DK3618842T3 (enExample) |
| ES (1) | ES2967467T3 (enExample) |
| FI (1) | FI3618842T3 (enExample) |
| IL (2) | IL270250B2 (enExample) |
| MA (1) | MA51871A (enExample) |
| MX (1) | MX2019012975A (enExample) |
| PH (1) | PH12019502470A1 (enExample) |
| PL (1) | PL3618842T3 (enExample) |
| PT (1) | PT3618842T (enExample) |
| SG (1) | SG11201910143TA (enExample) |
| WO (1) | WO2018204427A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3226897T3 (da) | 2014-12-05 | 2021-04-19 | Memorial Sloan Kettering Cancer Center | Antistoffer der rammer b-cellemodningsantigen og fremgangsmåder til anvendelse |
| US11821027B2 (en) | 2017-01-10 | 2023-11-21 | Juno Therapeutics, Inc. | Epigenetic analysis of cell therapy and related methods |
| SG11201907580SA (en) | 2017-02-17 | 2019-09-27 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| CN111148849A (zh) | 2017-05-26 | 2020-05-12 | 阿布维托有限责任公司 | 高通量多核苷酸文库测序和转录组分析 |
| CN111107874A (zh) * | 2017-09-14 | 2020-05-05 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
| BR112020008638A2 (pt) | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma) |
| CA3080904A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| AU2019372331A1 (en) | 2018-11-01 | 2021-05-27 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| MX2021005366A (es) * | 2018-11-08 | 2021-09-10 | Juno Therapeutics Inc | Metodos y combinaciones para el tratamiento y modulacion de celulas t. |
| KR20220003552A (ko) * | 2019-04-22 | 2022-01-10 | 스타트온 테라퓨틱스, 인크. | 레날리도미드 및 다른 면역조정제의 연속적 전달 |
| WO2020220027A1 (en) * | 2019-04-25 | 2020-10-29 | Purdue Research Foundation | Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same |
| CA3155667A1 (en) * | 2019-09-27 | 2021-04-01 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| EP4055383A1 (en) | 2019-11-05 | 2022-09-14 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
| MX2022005524A (es) * | 2019-11-07 | 2022-08-25 | Juno Therapeutics Inc | Combinacion de una terapia de celulas t y (s)-3-[4-(4-morfolin-4-i lmetil-benciloxi)-1-oxo-1,3-dihidro-isoindol-2-il]-piperidino-2,6 -diona. |
| IL293564A (en) * | 2019-12-06 | 2022-08-01 | Fate Therapeutics Inc | Enhancement of ipsc-derived effector immune cell using small compounds |
| TW202140790A (zh) * | 2020-01-22 | 2021-11-01 | 愛爾蘭商佧琺藥業有限公司 | 病毒載體轉導細胞的方法 |
| IL295381A (en) * | 2020-02-12 | 2022-10-01 | Juno Therapeutics Inc | bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof |
| KR20230031814A (ko) * | 2020-03-18 | 2023-03-07 | 메모리얼 슬로안 케터링 캔서 센터 | 항-세라마이드 항체 |
| JP7727662B2 (ja) | 2020-05-13 | 2025-08-21 | ジュノー セラピューティクス インコーポレイテッド | 臨床応答に関連する特徴量の特定方法およびその使用 |
| US20220193134A1 (en) * | 2020-12-23 | 2022-06-23 | Crispr Therapeutics Ag | Co-use of lenalidomide with car-t cells |
| CN112321713B (zh) * | 2020-12-31 | 2021-05-25 | 北京艺妙神州医药科技有限公司 | 一种抗bcma的抗体及其应用 |
| IL309914A (en) * | 2021-07-29 | 2024-03-01 | Takeda Pharmaceuticals Co | Immune cells express a chimeric antigen receptor that specifically targets mesothelin and their uses |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| PL195916B1 (pl) | 1996-07-24 | 2007-11-30 | Celgene Corp | Izomery optyczne podstawionej 1-okso-izoindoliny i 1,3-diokso-izoindoliny, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie |
| ATE533784T1 (de) | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | Lösliche, einzelkettige proteine des t- zellrezeptors |
| JP4695259B2 (ja) | 1998-03-16 | 2011-06-08 | セルジーン コーポレイション | ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用 |
| DK1066380T3 (da) | 1998-05-19 | 2002-01-28 | Avidex Ltd | Opløselig T-cellereceptor |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| AU771015B2 (en) | 1999-03-18 | 2004-03-11 | Celgene Corporation | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| ES2338534T3 (es) | 2001-02-27 | 2010-05-10 | The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services | Analogos de talidomina como inhibidores de la angiogenesis. |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| JP4317940B2 (ja) | 2001-08-31 | 2009-08-19 | イミュノコア・リミテッド | 物質 |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変ｔ細胞レセプターを発現する細胞 |
| US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| US7615883B2 (en) | 2007-06-06 | 2009-11-10 | Meheen H Joe | Wind driven venturi turbine |
| EP3338895B1 (en) | 2007-12-07 | 2022-08-10 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| HRP20161194T1 (hr) | 2009-03-10 | 2016-11-04 | Biogen Ma Inc. | Anti-bcma protutijela |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| RU2665548C2 (ru) | 2012-05-03 | 2018-08-30 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ получения клеток, экспрессирующих т-клеточный рецептор |
| PL2884999T3 (pl) | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| EA201691144A1 (ru) | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| EP3626748A1 (en) * | 2014-01-13 | 2020-03-25 | Stephen J. Forman | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| FI3888674T3 (fi) * | 2014-04-07 | 2024-07-02 | Novartis Ag | Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria |
| EP4008725A1 (en) | 2014-05-02 | 2022-06-08 | The Trustees of the University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| JP2017528433A (ja) * | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| WO2016014565A2 (en) * | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| SG10201900455YA (en) | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| PT3198345T (pt) | 2014-09-22 | 2021-02-25 | Sacmi | Linha para a produção de produtos individuais em sucessão num ciclo contínuo |
| SG10201900931XA (en) | 2014-12-05 | 2019-02-27 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| DK3226897T3 (da) | 2014-12-05 | 2021-04-19 | Memorial Sloan Kettering Cancer Center | Antistoffer der rammer b-cellemodningsantigen og fremgangsmåder til anvendelse |
| NZ733025A (en) | 2014-12-12 | 2022-01-28 | 2Seventy Bio Inc | Bcma chimeric antigen receptors |
| US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
| ES2876974T3 (es) * | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
| KR20180029201A (ko) * | 2015-05-18 | 2018-03-20 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법 |
| EP3313818B1 (en) * | 2015-06-26 | 2023-11-08 | Celgene Corporation | Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2017058754A1 (en) * | 2015-09-28 | 2017-04-06 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| PL3436079T3 (pl) | 2016-04-01 | 2021-12-20 | Kite Pharma, Inc. | Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania |
| KR20190084053A (ko) * | 2016-10-13 | 2019-07-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | 트립토판 대사 경로 조절인자 관련 면역 치료 방법 및 조성물 |
| ES2916335T3 (es) * | 2016-10-20 | 2022-06-30 | Celgene Corp | Receptores de antígeno quimérico heterodimerizable basados en cereblon |
| MX2019005029A (es) * | 2016-11-03 | 2019-10-24 | Juno Therapeutics Inc | Terapia de combinación de una terapia de células t y un inhibidor de tirosina cinasa de bruton (btk). |
| CA3040914A1 (en) * | 2016-11-03 | 2018-05-24 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia inhibitor |
| MA46995A (fr) * | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
| RU2019120398A (ru) * | 2016-12-03 | 2021-01-12 | Джуно Терапьютикс, Инк. | Способы определения дозировки cart-клеток |
| MA46961A (fr) * | 2016-12-03 | 2019-10-09 | Juno Therapeutics Inc | Procédés de modulation de lymphocytes t modifiés par car |
| CN109752300A (zh) | 2019-01-02 | 2019-05-14 | 五邑大学 | 一种涂料生产安全智能巡检机器人、系统及方法 |
-
2018
- 2018-05-01 CA CA3061945A patent/CA3061945A1/en active Pending
- 2018-05-01 IL IL270250A patent/IL270250B2/en unknown
- 2018-05-01 CN CN202410791051.4A patent/CN118948892A/zh active Pending
- 2018-05-01 KR KR1020247030601A patent/KR20240139092A/ko active Pending
- 2018-05-01 EP EP23203765.5A patent/EP4327878A3/en active Pending
- 2018-05-01 JP JP2019559744A patent/JP7299841B2/ja active Active
- 2018-05-01 PL PL18730161.9T patent/PL3618842T3/pl unknown
- 2018-05-01 IL IL310031A patent/IL310031A/en unknown
- 2018-05-01 AU AU2018263887A patent/AU2018263887B2/en active Active
- 2018-05-01 MX MX2019012975A patent/MX2019012975A/es unknown
- 2018-05-01 WO PCT/US2018/030545 patent/WO2018204427A1/en not_active Ceased
- 2018-05-01 KR KR1020197035525A patent/KR102707505B1/ko active Active
- 2018-05-01 SG SG11201910143T patent/SG11201910143TA/en unknown
- 2018-05-01 ES ES18730161T patent/ES2967467T3/es active Active
- 2018-05-01 US US16/609,733 patent/US20200078404A1/en active Pending
- 2018-05-01 MA MA051871A patent/MA51871A/fr unknown
- 2018-05-01 CN CN201880042831.1A patent/CN111182909A/zh active Pending
- 2018-05-01 DK DK18730161.9T patent/DK3618842T3/da active
- 2018-05-01 FI FIEP18730161.9T patent/FI3618842T3/fi active
- 2018-05-01 PT PT187301619T patent/PT3618842T/pt unknown
- 2018-05-01 EP EP18730161.9A patent/EP3618842B1/en active Active
- 2018-05-01 BR BR112019022893A patent/BR112019022893A2/pt unknown
-
2019
- 2019-10-31 PH PH12019502470A patent/PH12019502470A1/en unknown
-
2023
- 2023-06-16 JP JP2023098900A patent/JP2023116720A/ja active Pending
-
2025
- 2025-07-22 AU AU2025206408A patent/AU2025206408A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518591A5 (enExample) | ||
| Cohen et al. | How to train your T cells: overcoming immune dysfunction in multiple myeloma | |
| US20240261328A1 (en) | Use of cart19 to deplete normal b cells to induce tolerance | |
| CN113713095B (zh) | 用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体 | |
| KR102470294B1 (ko) | 암을 치료하기 위한 항-pd1 항체 및 방사선의 조합 | |
| AU2020374947C1 (en) | Anti-CD47 and anti-CD20 based treatment of blood cancer | |
| JP2019532997A5 (enExample) | ||
| JP2019536460A5 (enExample) | ||
| IL305621A (en) | Methods for training patients for T-cell therapy | |
| JP2020511462A5 (enExample) | ||
| WO2019144126A1 (en) | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells | |
| JP2020519579A (ja) | Ｌｒｒｃ３３阻害剤およびその使用 | |
| JPWO2020097403A5 (enExample) | ||
| EP4051710A1 (en) | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells | |
| Liu et al. | Targeting dendritic cells with a PD-L1 based bispecific antibody rejuvenates specific anti-tumor T cells | |
| Riller et al. | Tight interplay between therapeutic monoclonal antibodies and the tumour microenvironment in cancer therapy | |
| Klausz et al. | Potent Targeting of the Glycoantigen CD75s on Myeloma by the Tetravalent, Fc-Engineered Antibody ‘EBU-141 Tetra’ | |
| Sibéril | Tight Interplay Between Therapeutic Monoclonal | |
| RU2019138707A (ru) | Сочетание клеточной терапии и иммуномодуляторного соединения | |
| Kato | Therapeutic Monoclonal Antibodies for Cancer: The Past, Present, and Future | |
| US20180273897A1 (en) | Modified t-cells having anti-fugetactic properties and uses thereof | |
| Mellstedt | Immunotherapeutic approaches |